How far does universal access to affordable, quality healthcare depend on shareholder democracy?

WHO identifies cost as the primary barrier to access globally, with medicines representing the largest out-of-pocket health expense in low- and middle-income countries.

Pharmaceutical companies set list prices, negotiate confidential rebates, and control patient assistance programs that determine who can afford treatment. AbbVie's Humira, Bristol Myers Squibb's Revlimid, and Pfizer's portfolio illustrate how monopoly pricing blocks access. The same firms lobby Congress and the U.S. Trade Representative to oppose Medicare price negotiation and to embed patent extensions in trade agreements. The Pharmaceutical Research and Manufacturers of America (PhRMA) spent $29.4 million on lobbying in 2022, with member companies adding tens of millions more. When institutional owners vote alongside organizations pressing for access plans and transparency on R&D costs, they can shift board-level pricing strategy and disclosure. No other actor holds this lever; governments regulate prices in most wealthy nations but not in the United States, where corporate decisions govern access for the largest medicine market.

WHO and Gavi rank supply constraints and technology transfer failures as critical to ending preventable disease and achieving SDG 3.3.

Vaccine manufacturers control licensing terms, production capacity allocation, and know-how sharing that determine whether low-income countries can produce their own supplies. During COVID-19, Moderna and Pfizer declined to share mRNA technology with the WHO's technology transfer hub, while AstraZeneca licensed broadly through the Serum Institute of India. The International Federation of Pharmaceutical Manufacturers Associations lobbied against the TRIPS waiver for COVID-19 vaccines at the WTO. Corporate political influence here slows institutional innovation in global health architecture. Shareholder advocacy can push companies toward open licensing and technology transfer, but governments and multilateral bodies must also fund procurement and build manufacturing capacity. Owners voting alongside access advocates remove an obstacle that no consumer boycott or regulatory action alone can address, yet the outcome still requires public investment.

WHO projects a global shortage of 10 million health workers by 2030, concentrated in low- and lower-middle-income countries.

Training, deploying, and retaining health workers depends on public education financing, government salary scales, and immigration policy. Private healthcare employers operate in some markets, but the structural shortage of nurses, midwives, and community health workers reflects decades of underinvestment by ministries of finance and education. Corporate conduct contributes marginally through recruitment practices that can drain workers from public systems, but the decisive levers sit with governments and development banks. The World Bank's International Development Association and bilateral programs like the U.S. President's Emergency Plan for AIDS Relief fund workforce expansion. No plausible shareholder vote at a publicly traded company can train a million nurses or set their wages in the public sector where most work.

World Bank health system assessments consistently rank inadequate facility infrastructure and supply chains as core access barriers.

Clinics, clean water, reliable electricity, and transport networks for rural health delivery are public goods funded by taxation and development assistance. Construction companies may build facilities under contract, but the decision to build, the site selection, and the ongoing operational subsidy come from government budgets. The Global Fund to Fight AIDS, Tuberculosis and Malaria and Gavi, the Vaccine Alliance, channel most external financing. Private hospital chains operate in urban markets and some middle-income countries, yet they do not serve the populations most excluded from care. Shareholder democracy has no lever here; owners of construction or utility companies cannot vote for a clinic in a village that needs one.

UNICEF and WHO rank neonatal conditions, pneumonia, diarrhea, and malaria as leading causes of under-five mortality, all addressable with existing interventions.

Infant formula companies and some medical device manufacturers influence nutrition and obstetric care practices, but the mortality gap overwhelmingly reflects failures in health system reach: women delivering without skilled attendance, children with pneumonia going untreated, vaccines not arriving cold. Nestlé's historical conduct on formula marketing in low-income countries illustrates corporate harm, and shareholder advocacy has pressed for marketing code compliance. Yet the decisive obstacles are facility access, transport, and supply chain failures that corporate conduct does not govern. Corporate political influence is immaterial here. Owners voting on company conduct can help at the margin on marketing ethics, but cannot deliver the integrated services that reduce mortality.

WHO and the Global Health Security Agenda identify weak surveillance as a core vulnerability enabling pandemic emergence and spread.

Disease surveillance, vital registration, and health management information systems are public functions funded by governments and technical agencies like the U.S. Centers for Disease Control and Prevention and the WHO. Technology companies may provide platforms, but the data collection, laboratory networks, and reporting protocols are state-operated. During COVID-19, gaps in genomic sequencing capacity traced to years of public underinvestment, not corporate conduct. Private diagnostic companies expanded testing where profitable but withdrew as demand fell, leaving public health agencies to sustain surveillance. Shareholder advocacy cannot vote for a national laboratory network or a real-time mortality reporting system.

WHO ranks cardiovascular disease, cancer, diabetes, and depression as leading causes of disability and premature mortality globally.

Food and beverage companies formulate products with excessive sodium, sugar, and trans fats that drive diabetes and cardiovascular disease. Tobacco companies continue to market in jurisdictions with weak regulation. Shareholder advocacy has pressed food companies on nutrition and tobacco companies on marketing, with some success on disclosure. Yet mental health services and chronic disease management depend primarily on health system integration and public financing. The American Heart Association and mental health advocates lobby for parity laws and funding, not corporate conduct changes. Corporate political influence by food and tobacco industries blocks regulation, so shareholder pressure on lobbying matters, but governments must still build the treatment capacity.

WHO's Health Emergency Preparedness and Response framework and the Independent Panel for Pandemic Preparedness identify underinvestment in surge capacity as a critical gap.

Stockpiling personal protective equipment, maintaining reserve hospital capacity, and funding rapid response teams are public functions. The Strategic National Stockpile in the United States and equivalent programs elsewhere are government assets. Private hospital systems optimized for efficiency before COVID-19 and lacked surge capacity when demand spiked; they have no incentive to maintain expensive unused capacity. Medical supply companies produce to forecast demand, not to strategic reserve requirements. The PREVENT Pandemics Act and proposed international pandemic fund would channel public money. Shareholder democracy cannot maintain a national ventilator stockpile or fund a standing rapid response corps; these are inherently governmental.